New HIV injection LP-98 tested in small safety trial

NCT ID NCT06560489

Completed Disease control Sponsor: Shanxi Kangbao Biological Product Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called LP-98 in 40 people with HIV who had not taken any HIV medications before. Participants received different doses of LP-98 as a shot under the skin every two weeks for a total of four doses. The main goal was to check if the drug is safe and how the body handles it, not to see if it controls the virus. This is an early step in finding out if LP-98 could become a future treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LP-98
What this could lead to: If successful, this could point toward a new injectable treatment option for HIV that helps control the virus.
What could go wrong: This is a very early, small study focused on safety and dosing, not on proving the drug works. Many drugs fail in early trials, and it may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.